Historical record - last NADAC effective date: 10/5/2022
Product Information
AMZEEQ 4% FOAM is a brand product labeled by Journey Medical Corporation, priced at $15.5415 per GM under NDC 69489020130. Its NADAC has been published 20 times since Oct 5, 2022.
FDA first approved this application on Oct 18, 2019.
Strength
40 mg/g
Manufacturer
Journey Medical CorporationNDC
69489020130
Classification
Brand
Dosage Form
AEROSOL, FOAM
Route
TOPICAL
Effective Date
10/5/2022
Active Ingredients
MINOCYCLINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA212379FDA Approved
10/18/2019
On Market Since
3/25/2022
Pharmacological Classes
Price Statistics
The NADAC for AMZEEQ 4% FOAM has been published 20 times since Oct 5, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.5415 per GM |
|---|---|
| All-time high | $15.5415 (Feb 15, 2023) |
| All-time low | $15.5415 (Oct 5, 2022) |
| Median price | $15.5415 |
| Average price | $15.5415 |
| Largest weekly change | 0.0% (Oct 12, 2022) |
| Weeks tracked | 20 |
| Tracking since | Oct 5, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Feb 15, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Minocycline market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Journey Medical Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Minocycline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMZEEQ 4% FOAM?
The current National Average Drug Acquisition Cost (NADAC) for AMZEEQ 4% FOAM, manufactured by Journey Medical Corporation, is $15.5415 per GM (NDC 69489020130), effective Feb 15, 2023.
How has the price of AMZEEQ 4% FOAM changed over time?
Over the history we have for it, the NADAC for AMZEEQ 4% FOAM has held within roughly two percent of its current level. It has been tracked across 20 weekly CMS publications since Oct 5, 2022.
What are the highest and lowest recorded NADAC prices for AMZEEQ 4% FOAM?
Since Oct 5, 2022, the NADAC for AMZEEQ 4% FOAM has ranged from a low of $15.5415 (Oct 5, 2022) to a high of $15.5415 (Feb 15, 2023), with a median of $15.5415 per GM.
Are there cheaper alternatives to AMZEEQ 4% FOAM?
No other NADAC-published product currently shares the active ingredient and strength of AMZEEQ 4% FOAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AMZEEQ 4% FOAM?
AMZEEQ 4% FOAM (NDC 69489020130) is labeled by Journey Medical Corporation, and CMS classifies it as a brand product.